AccessHope Expands Cancer Care Offerings with New AI Capabilities, Supportive Oncology, Clinical Trials, and International Expert Reviews

Claims-validated analysis showing average total cost-of-care reduced 10% to 30% per adopted recommendation

DUARTE, Calif., Nov. 12, 2026 /PRNewswire/ -- AccessHope, a company expanding access to world-class cancer care, today announced significant enhancements to its nationally deployed cancer expertise model, with integrated AI capabilities, supportive oncology, international expert reviews and expanded clinical trials offerings.

In addition, a new independently validated actuarial methodology and analysis of claims data show that the AccessHope model can reduce the average total cost of care by 10% to 30% per adopted recommendation in one year. By providing evidence-based subspecialist guidance to community oncologists at critical points in a patient's cancer journey, AccessHope helps improve treatment quality and outcomes, while reducing total cost of care.

"Our model is central to what matters most in cancer care: getting every patient the right treatment at the right time," said AccessHope CEO Brad Kreick. "We've also proven that better cancer care doesn't have to cost more. When subspecialist guidance reaches community oncologists at the moment decisions are made, patients can get the right therapy faster, while employers see validated savings in the first year. The precision of our technology and AI-enabled solution deliver that expertise while measuring adoption, outcomes and ROI."

Solution Enhancements Advance Equitable Cancer Care

AccessHope is advancing its evidence‑based cancer expertise model with enhancements designed to strengthen equity and access to cancer care, deepen clinical integration, and ensure every member receives the same high‑standard subspecialist guidance. New offerings include: 

• New AI capabilities, powered by proprietary large language models, outcome-linked claims data and guidelines from National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO), and the most recent clinical evidence. Combining AI with oncology clinician judgment, the guideline-grounded technology identifies patients who could benefit, accelerates case reviews and improves accuracy. Every recommendation is made and approved by a named, practicing cancer subspecialist from an National Cancer Institute-Designated Comprehensive Cancer Center (NCI-CCC). The technology then tracks adoption of those recommendations in claims data and measures outcomes in real-world care, helping validate clinical impact and value. Oncology clinicians oversee both identification and validation.
• Supportive oncology, which embeds expert guidance on symptoms and wellbeing in every expert review, adds palliative care specialist recommendations for late-stage patients, and gives members and families access to nurses and digital tools, improving care experiences and reducing total cost of care.
• New clinical trial capabilities, which build on the Clinical Trials program launched in October 2025. AccessHope automatically identifies potential trial matches alongside subspecialist expert reviews and connects patients with a trial support specialist who can assist with enrollment and logistics of care.
• International expert reviews, which provide access to subspecialist review for members living outside of the United States, enabling employers with global workforces to extend these benefits companywide.

Strengthening Community Oncology at the Moment It Matters Most

Cancer is fundamentally different from chronic conditions like diabetes, hypertension and heart conditions, where patient behavior drives results. In cancer, outcomes hinge on whether the oncologist reaches the right clinical decision.

At NCI-CCCs, subspecialists focus on a single type of cancer, allowing them to keep pace with the latest evidence, conduct and publish research, and help develop clinical guidelines. Yet just 20% of cancer patients are treated at NCI-CCCs, leaving most community oncologists without that specialized expertise readily available.

"With new therapies, biomarkers and guidelines emerging at an unprecedented pace, no community oncologist can be expected to keep up with every advancement across all cancer types," said Yousuf Zafar, MD, MHS, FASCO, chief medical officer for AccessHope. "Our role is to bring subspecialty expertise directly into the care team at critical moments, supporting rather than replacing the community oncologists patients know and trust. With expanded supportive oncology and clinical trial services and AI-enabled capabilities, we can extend that expertise throughout the cancer journey to help improve outcomes and lower costs."

Adopted Expert Recommendations Deliver an Average of $32,000 in Annual Total Cost of Care Savings Per Patient

By grounding every recommendation in evidence-based guidelines, AccessHope's model can also deliver a measurable financial return. This rigor carries through to the company's savings methodology, which relies exclusively on confirmed claims‑validated reductions in total cost of care.

AccessHope's total cost of care savings methodology has been independently validated by Accorded, a data and actuarial services company. The methodology reflects more than six years of utilization experience, rigorous testing assumptions, and claims-based validation of adopted treatment plan changes. The analysis found that AccessHope reduces total cost of care by an average of $32,000 in savings per patient with an adopted recommendation, per year. This can reduce the average total cost of care by 10% to 30% per adopted recommendation in one year. The savings reinforces that better care and lower costs do not have to be a trade-off.

For example, in one patient with EGFR-mutated lung cancer, an actionable mutation was initially missed, resulting in $339,000 in total costs over 12 months with a 30% two-year survival probability. With subspecialist review before treatment began, the patient received targeted therapy, costing $238,000 and carrying an 86% two-year survival probability. The total cost of care was less with the more clinically precise treatment.

More information on this financial analysis is available in the recently released report, A Proven Path to Better Cancer Outcomes and Lower Costs: A Scalable Solution for Health Plans and Employers.

About AccessHope
AccessHope helps people access world-class cancer expertise without leaving the care team they trust. Through partnerships with National Cancer Institute-designated Comprehensive Cancer Centers, AccessHope brings subspecialty cancer expertise into local communities through a physician-to-physician model that supports treating oncologists with evidence-based recommendations tailored to each patient's specific diagnosis. By combining advanced technology with expert clinical oversight, AccessHope automatically identifies patients who may benefit and measures real-world adoption and outcomes. Today, AccessHope serves more than 10 million members through over 800 organizations, including more than 80 Fortune 500 companies. For more information, visit myaccesshope.org and follow us on LinkedIn.

SOURCE AccessHope